Learn / 1 Sept 2026

Eli Lilly and Company (NYSE: LLY): Shariah Screening & ESG Profile

As a global biopharmaceutical heavyweight pioneering breakthroughs in metabolic health (GLP-1/GIP therapies), oncology, neuroscience (Alzheimer’s), and immunology, Eli Lilly and Company (NYSE: LLY) serves as a primary healthcare benchmark for qualitative Shariah permissibility, AAOIFI balance sheet compliance, and institutional ESG access-to-medicine evaluation.

Sector Screening

1. Core Business Activity & Permissibility

Eli Lilly discovers, develops, manufactures, and markets clinical pharmaceuticals and therapeutic formulations worldwide:

Status: Permissible

Biopharmaceuticals & Therapeutics

Developing life-saving medications for diabetes, obesity, cancer, and neurodegenerative conditions directly aligns with the Islamic objective of preserving human life (Hifz al-Nafs) and is permissible (Halal).

Purification Area

Treasury Yields & Royalties

Incidental income from global cash deposits, liquidity investments, and non-operating financial yields requires regular dividend purification calculation.

Quantitative Screen

2. AAOIFI Financial Ratio Compliance (LLY)

Financial metrics are evaluated against the quantitative debt and liquidity ceilings outlined in AAOIFI Shariah Standard No. 21 relative to market valuation:

Screening Metric	AAOIFI Standard Limit	Eli Lilly Status	Compliance Verdict
Interest-Bearing Debt / Market Cap	< 30.00%	Long-term manufacturing expansion bonds remain heavily diluted by mega-cap valuation (< 5%).	Compliant
Interest-Bearing Cash / Market Cap	< 30.00%	Cash, bank deposits, and liquid short-term investments remain safely below the 30% limit (< 2%).	Compliant
Illiquid Assets / Total Assets	≥ 30.00%	Backed by advanced global manufacturing campuses, clinical research laboratories, inventory, and patent portfolios.	Compliant
Non-Permissible Revenue Ratio	< 5.00%	Incidental finance income and non-operating yields account for less than 1% of total gross revenue.	Purification Required

ESG Scorecard

3. Environmental, Social, and Governance (ESG) Audit

Eli Lilly’s sustainability performance is driven by extensive access-to-healthcare programs, continuous clinical trial transparency, and pharmaceutical environmental safety:

Environmental (E) AA • Strong

Pharmaceutical Waste & Solar Energy

100% renewable electricity transition targets for major manufacturing sites, eco-friendly autoinjector pen recycling, and strict control of Active Pharmaceutical Ingredients (API) in wastewater.

Social (S) AAA • Leader

Medicine Access & Affordability

Global insulin price-capping programs ($35/month Lilly Insulin Value Program), non-profit tiered pricing for low-to-middle income countries, and diverse clinical trial representation.

Governance (G) AA • Strong

Bioethics & Drug Pricing Oversight

Independent board oversight, stringent global compliance against healthcare provider bribery (FCPA), and high disclosure integrity in clinical trial endpoints.

Executive Summary

4. Screening Verdict & Portfolio Takeaways

✅

          Overall Verdict: Shariah-Compliant & Top-Tier ESG Healthcare Leader

          Eli Lilly and Company passes all qualitative Shariah sector screens and easily clears AAOIFI quantitative financial ratio limits. Islamic equity investors receiving dividend payouts must calculate and purify the minor non-operating interest income percentage in accordance with dividend purification rules.

Disclaimer: This equity screening case study is prepared strictly for analytical and educational purposes based on AAOIFI Shariah standards and institutional ESG disclosure metrics. It does not constitute formal religious rulings (Fatwas) or financial investment advice.

Information only. Purindex does not recommend buying, selling or holding any security.